An observational study in HIV Infections, sponsored by The HIV Netherlands Australia Thailand Research Collaboration. Recruiting at 1 site in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by The HIV Netherlands Australia Thailand Research Collaboration · Observational
Among 28 studies in HIV Infections by The HIV Netherlands Australia Thailand Research Collaboration — 1 open to participants now, 1 under way, none of them phase 3. HIV Infections · The HIV Netherlands Australia Thailand Research Collaboration.
Among the 28 studies in HIV Infections by The HIV Netherlands Australia Thailand Research Collaboration, this one is the only one that started in 2002, is one of 9 observational ones, and was the 4th registered.
4,735 studies on the registry are indexed under HIV Infections; 245 are open to participants now.
Browse HIV Infections studies →1 of the 28 studies in HIV Infections by The HIV Netherlands Australia Thailand Research Collaboration is open now, in 1 country.
By country, each count listing its studies:
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 13 · Phase 4 5
First in 2002; this study’s year is marked. 1 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 200 across 781 observational studies indexed under HIV Infections.
Median enrollment 40 across the 19 interventional studies, 450 across the 9 observational. Of the 26 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
The HIV Netherlands Australia Thailand Research Collaboration is the lead sponsor of 60 studies on the registry; 1 is open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 28 studies in HIV Infections by The HIV Netherlands Australia Thailand Research Collaboration, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
With HIV/AIDS increasingly considered a chronic disease, 24-, or 48-week data from antiretroviral studies are no longer sufficient. Only with long-term follow-up and outcome data will shed some much-needed light on the answers of questions that have stumped us for several years. Data from a large observational cohort of patients treated with combination antiretroviral therapy will provide further insights into the long-term safety and durability of various antiretroviral therapeutic approached, the efficacy of HIV viral load and CD4 cell counts as predictors of disease progression and mortality, and the importance of adherence.
Primary Objective:
To collect and evaluate long-term clinical outcomes of HIV infected participants previously enrolled in HIV-NAT trials.
Secondary Objective:
To Assess:
All HIV infected adult patients from HIV-NAT.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV infection
This cohort will collect various information such as but not limited to: comorbidity, mortality, cardiovascular, neurological clinical data, treatment history, serious adverse events, PBMCs, clinical outcomes, virological outcomes, resistance, failure, aging, other opportunistic infections, etc
Time frame: 30 years
Started Nov 2002 (actual). Primary completion is estimated for Dec 2030, 337 months after the start.
Of 187 non-industry observational studies under HIV Infections, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 337 months is above that.
Counting every sponsor, half of 201 studies reached it within 38 months; a quarter within 16 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The HIV Netherlands Australia Thailand Research Collaboration